Pfizer drug helps patients lose weight

Diabetes drug Pfizer Inc. resulted in the same weight loss as Novo Nordisk’s Ozempic in an interim study in patients with type 2 diabetes.

Pfizer shares up about 4.5% after hearing the news that comes at a time when investors are showing more interest in the weight loss market, which is estimated to reach $100,000 million by the end of the decade.

He danuglipron Pfizer administered twice a day lowered patients’ blood sugar levels at all doses and body weight at the highest dose after 16 weeks compared to placebo, according to interim phase data published last year by an American drug manufacturer.

The study involved 411 adults with type 2 diabetesreceiving drug or placebo.

Weight loss with danuglipron is similar to that observed in the mean data for semaglutide from new nordiskknown as Ozempic when used for diabetes and Wegovy for obesity.

Ozempic was first approved in 2017 for the treatment of diabetes and Vegovi for weight loss in the USA in 2021.

Drugs, including Pfizer’s danuglipron, are in a class of drugs that intestinal hormone mimic peptide similar to glucagon type 1 (GLP-1), which acts by suppressing appetite and was originally developed to treat type 2 diabetes.

Pfizer is also testing oral medications for diabetes, once-daily lotiglipron, and said it plans to enter late-stage development of only one of the two candidates. The company believes that oral therapy may appeal to patients who want to avoid injections.

Reuters

Source: Aristegui Noticias

follow:
\